NS Pharma Announces Launch of Expanded Access Program for Viltolarsen
NS Pharma, Inc. has announced the launch of the viltolarsen Expanded Access Program in the United States for patients with Duchenne muscular dystrophy who are amenable to exon 53 skipping therapy and meet other eligibility…Learn More